AllSci News
Chipscreen puts PRMT5 inhibitor into Phase I for MTAP-deleted solid tumors and lymphoma
Chengdu Chipscreen Pharmaceuticals, a subsidiary of Shenzhen-based Chipscreen Biosciences (SSE: 688321), has registered a first-in-human clinical trial for...
Vertex Pharma expands neurology pipeline with first-in-human trial for small-molecule narcolepsy drug
Vertex Pharmaceuticals is advancing VX-433, an oral investigational compound, into a first-in-human Phase I clinical trial targeting narcolepsy type 1, a...
FDA approves expanded dosing regimen for Kyowa Kirin’s Crysvita in adult XLH
Japan’s Kyowa Kirin, Inc. (JPX: 4151.T) has received US FDA approval for an updated dosing regimen for Crysvita (burosumab-twza) in adults with…
Mirum Pharma issues USD 600m convertible notes to refinance 2029 debt, fund rare disease acquisitions
Foster City, California-based Mirum Pharmaceuticals (Nasdaq: MIRM) has announced the pricing of USD 600 million in aggregate principal of 0.00% convertible...
Gilead fills acquisitions war chest with USD 3b senior note offering
Gilead Sciences (Nasdaq: GILD) has announced the pricing of USD 3 billion in senior unsecured notes across four tranches in an underwritten registered...
Akeso's ligufalimab shows 80% response rate in Phase II treatment-naïve AML trial
Akeso (HKEX: 9926.HK) reported Phase II data from its ligufalimab AML trial showing an objective response rate of 80.0% versus 66.7% for placebo in...
Chengdu Origen and Vanotech receive FDA clearance for KHN921 gene therapy in hypertrophic cardiomyopathy
Chengdu Origen Biotechnology and Vanotech have received US FDA clearance to proceed with a Phase I/II clinical trial of KHN921, an AAV9-based gene therapy...
HCW Biologics' fusion immunotherapeutic prevents bronchopulmonary dysplasia in preclinical models
HCW Biologics reports HCW11-040 prevents bronchopulmonary dysplasia in IND-enabling animal studies
CapeHaven completes first close toward USD 10 million seed funding for Yale biotech spinouts
CapeHaven launches Yale biotech spinout vehicle with USD 10 million target
Biogen completes USD 3.2b acquisition of Apellis Pharma for complement inhibitor assets
Biogen (Nasdaq: BIIB) has completed its acquisition of Apellis Pharmaceuticals, adding two commercially approved complement inhibitors and an established...
Taiwan's Bora Pharma adds MacroGenics' GMP manufacturing for USD 127.5m
Taiwan-based Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) has agreed to acquire the GMP manufacturing operations of MacroGenics (Nasdaq: MGNX) for USD...
In vivo CAR-T funding continues to flow as Create Medicines raises USD 122m in Series B
CREATE Medicines raises USD 122 million Series B to advance in vivo CAR pipeline
AstraZeneca's Imfinzi plus Padcev improves survival in muscle-invasive bladder cancer
AstraZeneca (LSE/STO/NYSE: AZN) has reported positive VOLGA trial results in bladder cancer, with perioperative durvalumab (Imfinzi) combined with...
GT Biopharma's B7-H3-targeted NK cell engager enters Phase I testing across solid tumors
GT Biopharma (Nasdaq: GTBP), based in San Francisco, has dosed the first patient in a Phase I basket trial evaluating GTB-5550, a B7-H3-targeted natural...
Degron Therapeutics closes USD 40 million Series A extension for molecular glue degraders
A targeted protein degradation company with a clinical-stage molecular glue degrader program has secured additional capital to fund its lead oncology asset...
The AllSci Brief
Systematic R&D and deal news. Daily.